Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting.

Julg B, Dee L, Ananworanich J, Barouch DH, Bar K, Caskey M, Colby DJ, Dawson L, Dong KL, Dubé K, Eron J, Frater J, Gandhi RT, Geleziunas R, Goulder P, Hanna GJ, Jefferys R, Johnston R, Kuritzkes D, Li JZ, Likhitwonnawut U, van Lunzen J, Martinez-Picado J, Miller V, Montaner LJ, Nixon DF, Palm D, Pantaleo G, Peay H, Persaud D, Salzwedel J, Salzwedel K, Schacker T, Sheikh V, Søgaard OS, Spudich S, Stephenson K, Sugarman J, Taylor J, Tebas P, Tiemessen CT, Tressler R, Weiss CD, Zheng L, Robb ML, Michael NL, Mellors JW, Deeks SG, Walker BD.

Lancet HIV. 2019 Apr;6(4):e259-e268. doi: 10.1016/S2352-3018(19)30052-9. Epub 2019 Mar 15. Review.

PMID:
30885693
2.

Highlights from the Fourth Biennial Strategies for an HIV Cure Meeting, 10-12 October 2018, Bethesda, MD, USA.

Kuo L, Lawrence D, McDonald D, Refsland E, Bridges S, Smiley S, Tressler RL, Beaubien C, Salzwedel K.

J Virus Erad. 2019 Jan 1;5(1):50-59.

3.

Highlights from the 8th International Workshop on HIV Persistence during Therapy, 12-15 December 2017, Miami, FL, USA.

Psomas CK, Lafeuillade A, Margolis D, Salzwedel K, Stevenson M, Chomont N, Poli G, Routy JP.

J Virus Erad. 2018 Apr 1;4(2):132-142.

4.

Highlights from the Third Biennial Strategies for an HIV Cure Meeting: 14-16 November 2016, Bethesda, MD, USA.

Lawrence D, Kuo L, Church E, Poon B, Smiley S, Sanders-Beer B, Dawson L, Salzwedel K.

J Virus Erad. 2017 Jan 1;3(1):69-76.

5.

Highlights from the Seventh International Workshop on HIV Persistence during Therapy, 8-11 December 2015, Miami, Florida, USA.

Margolis DM, Salzwedel K, Chomont N, Psomas C, Routy JP, Poli G, Lafeuillade A.

J Virus Erad. 2016 Jan 1;2(1):57-65.

6.

The prototype HIV-1 maturation inhibitor, bevirimat, binds to the CA-SP1 cleavage site in immature Gag particles.

Nguyen AT, Feasley CL, Jackson KW, Nitz TJ, Salzwedel K, Air GM, Sakalian M.

Retrovirology. 2011 Dec 7;8:101. doi: 10.1186/1742-4690-8-101.

7.

A single polymorphism in HIV-1 subtype C SP1 is sufficient to confer natural resistance to the maturation inhibitor bevirimat.

Lu W, Salzwedel K, Wang D, Chakravarty S, Freed EO, Wild CT, Li F.

Antimicrob Agents Chemother. 2011 Jul;55(7):3324-9. doi: 10.1128/AAC.01435-10. Epub 2011 Apr 18.

8.

Polymorphisms in Gag spacer peptide 1 confer varying levels of resistance to the HIV- 1 maturation inhibitor bevirimat.

Adamson CS, Sakalian M, Salzwedel K, Freed EO.

Retrovirology. 2010 Apr 20;7:36. doi: 10.1186/1742-4690-7-36.

9.

Elevated temperature triggers human respiratory syncytial virus F protein six-helix bundle formation.

Yunus AS, Jackson TP, Crisafi K, Burimski I, Kilgore NR, Zoumplis D, Allaway GP, Wild CT, Salzwedel K.

Virology. 2010 Jan 20;396(2):226-37. doi: 10.1016/j.virol.2009.10.040. Epub 2009 Nov 18.

10.
11.

Virus maturation as a new HIV-1 therapeutic target.

Adamson CS, Salzwedel K, Freed EO.

Expert Opin Ther Targets. 2009 Aug;13(8):895-908. doi: 10.1517/14728220903039714. Review.

12.

Anti-AIDS agents. 78. Design, synthesis, metabolic stability assessment, and antiviral evaluation of novel betulinic acid derivatives as potent anti-human immunodeficiency virus (HIV) agents.

Qian K, Yu D, Chen CH, Huang L, Morris-Natschke SL, Nitz TJ, Salzwedel K, Reddick M, Allaway GP, Lee KH.

J Med Chem. 2009 May 28;52(10):3248-58. doi: 10.1021/jm900136j.

13.

Impact of human immunodeficiency virus type 1 resistance to protease inhibitors on evolution of resistance to the maturation inhibitor bevirimat (PA-457).

Adamson CS, Waki K, Ablan SD, Salzwedel K, Freed EO.

J Virol. 2009 May;83(10):4884-94. doi: 10.1128/JVI.02659-08. Epub 2009 Mar 11.

14.

Susceptibility of human immunodeficiency virus type 1 to the maturation inhibitor bevirimat is modulated by baseline polymorphisms in Gag spacer peptide 1.

Van Baelen K, Salzwedel K, Rondelez E, Van Eygen V, De Vos S, Verheyen A, Steegen K, Verlinden Y, Allaway GP, Stuyver LJ.

Antimicrob Agents Chemother. 2009 May;53(5):2185-8. doi: 10.1128/AAC.01650-08. Epub 2009 Feb 17.

15.

Bevirimat: a novel maturation inhibitor for the treatment of HIV-1 infection.

Martin DE, Salzwedel K, Allaway GP.

Antivir Chem Chemother. 2008;19(3):107-13. Review.

PMID:
19024627
16.

Maturation inhibitors: a new therapeutic class targets the virus structure.

Salzwedel K, Martin DE, Sakalian M.

AIDS Rev. 2007 Jul-Sep;9(3):162-72. Review.

PMID:
17982941
17.

Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3',3'-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection.

Smith PF, Ogundele A, Forrest A, Wilton J, Salzwedel K, Doto J, Allaway GP, Martin DE.

Antimicrob Agents Chemother. 2007 Oct;51(10):3574-81. Epub 2007 Jul 16.

18.

In vitro resistance to the human immunodeficiency virus type 1 maturation inhibitor PA-457 (Bevirimat).

Adamson CS, Ablan SD, Boeras I, Goila-Gaur R, Soheilian F, Nagashima K, Li F, Salzwedel K, Sakalian M, Wild CT, Freed EO.

J Virol. 2006 Nov;80(22):10957-71. Epub 2006 Sep 6.

19.

Determinants of activity of the HIV-1 maturation inhibitor PA-457.

Li F, Zoumplis D, Matallana C, Kilgore NR, Reddick M, Yunus AS, Adamson CS, Salzwedel K, Martin DE, Allaway GP, Freed EO, Wild CT.

Virology. 2006 Dec 5-20;356(1-2):217-24. Epub 2006 Aug 22.

20.

3-O-(3',3'-dimethysuccinyl) betulinic acid inhibits maturation of the human immunodeficiency virus type 1 Gag precursor assembled in vitro.

Sakalian M, McMurtrey CP, Deeg FJ, Maloy CW, Li F, Wild CT, Salzwedel K.

J Virol. 2006 Jun;80(12):5716-22.

21.

PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing.

Li F, Goila-Gaur R, Salzwedel K, Kilgore NR, Reddick M, Matallana C, Castillo A, Zoumplis D, Martin DE, Orenstein JM, Allaway GP, Freed EO, Wild CT.

Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13555-60. Epub 2003 Oct 22.

22.
25.
27.

Identification of CX3CR1. A chemotactic receptor for the human CX3C chemokine fractalkine and a fusion coreceptor for HIV-1.

Combadiere C, Salzwedel K, Smith ED, Tiffany HL, Berger EA, Murphy PM.

J Biol Chem. 1998 Sep 11;273(37):23799-804.

29.

Expression and characterization of glycophospholipid-anchored human immunodeficiency virus type 1 envelope glycoproteins.

Salzwedel K, Johnston PB, Roberts SJ, Dubay JW, Hunter E.

J Virol. 1993 Sep;67(9):5279-88.

Supplemental Content

Loading ...
Support Center